- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/18 - Antivirals for RNA viruses for HIV
Patent holdings for IPC class A61P 31/18
Total number of patents in this class: 4212
10-year publication summary
|
156
|
186
|
162
|
256
|
300
|
316
|
319
|
267
|
232
|
58
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 1879 |
218 |
| ViiV Healthcare UK (no.5) Limited | 86 |
76 |
| Bristol-myers Squibb Company | 5080 |
66 |
| Duke University | 2872 |
61 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
60 |
| Mondobiotech Laboratories AG | 311 |
56 |
| ViiV Healthcare Company | 146 |
51 |
| Centre National de La Recherche Scientifique | 9632 |
50 |
| Merck Sharp & Dohme LLC | 3689 |
48 |
| Merck Sharp & Dohme Corp. | 2247 |
45 |
| The Scripps Research Institute | 1364 |
37 |
| F. Hoffmann-La Roche AG | 7958 |
33 |
| Shionogi & Co., Ltd. | 914 |
32 |
| The Regents of the University of California | 18943 |
28 |
| Janssen Vaccines & Prevention B.V. | 337 |
28 |
| Cipla Limited | 469 |
27 |
| Emory University | 1498 |
27 |
| Janssen Sciences Ireland Unlimited Company | 431 |
27 |
| Tibotec Pharmaceuticals Ltd. | 83 |
26 |
| Boehringer Ingelheim International GmbH | 4629 |
23 |
| Other owners | 3193 |